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Clinical Case Report
ABSTRACT
Background: Myelodysplastic syndromes (MDS) mainly occur in the elderly but can rarely affect younger individuals 
too. The correct diagnosis relies on careful morphologic evaluation, cytogenetic/molecular results, and excluding reactive 
conditions mimicking MDS. We present the clinical, pathologic, cytogenetic, and molecular features of a case of MDS 
with excess blasts-2 (MDS-EB-2) in a 30-year-old male who was found to have pancytopenia during his hospitalization 
for coronavirus disease 2019 (COVID-19) and discuss the diagnostic challenges of MDS in patients with COVID-19. 
Case presentation: A 30-year-old man presented to an outside hospital with fever, chills, weakness, coughing spells, 
dizziness and shortness of breath and was diagnosed with bilateral pneumonia due to COVID-19. At the outside 
hospital, he was found to be pancytopenic, and a subsequent bone marrow aspiration and biopsy raised concern for a 
COVID-19 induced hemophagocytic lymphohistiocytosis. In addition, MDS could not be ruled out. The patient was thus 
referred to our institute for further management. The patient’s peripheral blood showed pancytopenia with occasional 
dysplastic neutrophils and a few teardrop cells. Given the diagnostic uncertainty, a bone marrow aspiration and a biopsy 
were repeated revealing a hypercellular bone marrow with erythroid hyperplasia, megakaryocytic hyperplasia, trilineage 
dysplasia, increased blasts (13%), many ring sideroblasts, and mild to moderate myelofibrosis, consistent with MDS-EB-2. 
Chromosomal analysis revealed isochromosome 14. Next generation sequencing demonstrated SF3B1 K700E mutation. 
Discussion and conclusion: The diagnosis of MDS can be challenging, particularly in young patients. Cytopenia and 
myelodysplastic features have been reported in COVID-19 patients, making the diagnosis of MDS more elusive. A careful 
pathologic examination of the bone marrow with ancillary studies including flow cytometry, immunohistochemistry, and 
cytogenetic and molecular studies in combination with a thorough clinical evaluation, leads to the accurate diagnosis. 
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INTRODUCTION
Myelodysp last ic  syndromes (MDS)  are  a 
heterogeneous group of clonal hematological conditions 
affecting the hematopoietic stem cells in the bone 
marrow, associated with ineffective hematopoiesis, and 
manifesting as peripheral cytopenias and morphologic 
dysplasia in hematopoietic elements with less than 
20% blasts in blood or bone marrow. They are also 
characterized by recurrent genetic abnormalities and 
an increased risk of developing acute myeloid leukemia 
(AML). The bone marrow is often hypercellular. MDS 
primarily affect elderly patients. According to the 
Surveillance, Epidemiology and End Results (SEER) 
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database, only about 3-6% of MDS patients are less 
than 50 years old at the time of diagnosis.1,2 There are 
several subtypes of MDS, including MDS with single 
lineage dysplasia (MDS-SLD), MDS with multilineage 
dysplasia (MDS-MLD), MDS with ring sideroblasts 
(MDS-RS), MDS with isolated del(5q) (MDS/del5q), 
MDS with excess blasts (MDS-EB), MDS, unclassifiable 
(MDS-U), and refractory cytopenia of childhood 
(provisional diagnosis).3 This classification considers 
blood and bone marrow blast proportion, the number 
of myeloid lineages exhibiting significant dysplastic 
changes (i.e., at least 10% of cells in a lineage 
demonstrate dysplastic features morphologically), 
the presence of ring sideroblasts or Auer rods, and, 
to a limited extent, karyotype [del(5q)] and molecular 
genetic finding (SF3B1 mutation). Accurate diagnosis 
and classification of MDS relies on careful evaluation 
of high-quality peripheral blood and bone marrow 
aspirate smears, adequate bone marrow biopsies, 
karyotype and molecular genetic results, as well as 
clinical information.
Here we describe a unique case of MDS-EB2 in a 
30-year-old male patient with coronavirus disease 2019 
(COVID-19), in whom the diagnosis was a challenge.
CASE REPORT
A previously healthy 30-year-old man presented 
to an outside hospital with fever, chills, weakness, 
coughing spells, dizziness and shortness of breath. 
His chest X-ray showed bilateral lung with multifocal 
peripheral consolidation, highly suspicious for COVID-
19 pneumonia. Subsequent testing confirmed 
SARS-CoV-2, and he was diagnosed with bilateral 
pneumonia due to COVID-19. His blood culture was 
reported as no growth. Vital signs remained stable and 
he did not require any supplemental oxygen. However, 
he was found to be pancytopenic, with macrocytic 
anemia and an inappropriately low reticulocyte count. 
He was also found to have hyperferritinemia (ferritin 
level >100,000 ng/mL). His vitamin B12, iron, folate, 
haptoglobin levels were all within reference ranges, 
with no evidence of hemolysis. He had quit drinking 
alcohol 2 years ago and had no recent illicit substance 
use. An ultrasound-guided bone marrow aspiration 
and biopsy was performed 5 days later, to evaluate 
the pancytopenia. Per outside bone marrow report, his 
complete blood count (CBC) on the day of the bone 
marrow biopsy showed marked macrocytic anemia 
(RBC 2.23 M/cumm, Hgb 8.3 g/dL, hematocrit 24.3%, 
MCV 108.6 fL, MCH 37.2 pg, RDW 26.0%), moderate 
leukopenia (WBC 2.7 K/cumm), and moderate 
thrombocytopenia (45 K/cumm). His peripheral blood 
smear showed leukoerythroblastosis. His bone marrow 
aspirate and biopsy revealed a hypercellular bone 
marrow (85%) with marked erythroid hyperplasia 
and dysplasia, marked megakaryocytic hyperplasia, 
13-14% blasts, and evidence of hemophagocytosis 
(slides not available for review). The findings raised 
concern for a COVID-19-induced hemophagocytic 
lymphohistiocytosis (HLH). In addition, a high-grade 
myelodysplastic syndrome could not be ruled out. The 
patient was thus referred to Harbor-UCLA Medical 
Center for further management after being tested 
negative for SARS-CoV-2 twice.
The patient presented at Harbor-UCLA Medical 
Center on the Day16 after initial symptoms, feeling 
well without fever/chills, weight loss, dizziness/
lightheadedness, sweating, or pain. He had no history 
of exposure to pesticides, benzene, or other substances 
that may cause MDS. He denied recent alcohol, 
tobacco, or illicit drug use. The only medications 
he took were acetaminophen and ibuprofen in 
the previous month. He had no family history of 
hematologic malignancy. At presentation, the patient 
had an oral temperature of 36.9 °C, a heart rate of 92 
beat/minute, blood pressure of 122/70 mmHg, and a 
respiratory rate of 18 breaths/min. The physical exam 
and chest X-ray were unremarkable. No splenomegaly 
was noted. A CBC showed moderate normochromic-
macrocytic anemia (RBC 2.52 M/cumm, normal range 
4.40-5.60 M/cumm; Hgb 9.4 g/dL, normal range 
13.5 -16.5 g/dl; hematocrit 28.3%, normal range 
40.0-49.0%; MCV 112.3 fL, normal range 82.0 -97.0 
fL; MCH 37.4 pg, normal range 27.0-33.0 pg; MCHC 
33.3 g/dL, normal range 32.0 – 35.0 g/dL; RDW 26.2%, 
normal range 12.0-15.0%), moderate leukopenia 
(WBC 2.6 K/cumm, normal range 4.5 -10.0 K/cumm; 
100-cell manual differential: neutrophils 47%, 
lymphocytes 51%, monocyte 1%, and eosinophil 1%), 
and moderate thrombocytopenia (69 K/cumm, normal 
range 160-360 K/cumm) with increased large/giant 
platelets (MPV 12.9 fL, normal range 7.0-11.0 fL). 
Review of the peripheral blood smears revealed a 
leukoerythroblastic picture with occasional dysplastic 
neutrophils and a few teardrop cells (Figure 1).
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Additional blood tests were performed, and the 
test results are summarized in Table 1.
Given the diagnostic uncertainty, a bone marrow 
aspiration and biopsy were repeated 20 days after 
the presentation at Harbor-UCLA Medical Center. 
The smears of bone marrow aspirate contained 
rare spicules showing marked erythroid hyperplasia 
and scattered blasts (Figure 2), without evidence 
of hemophagocytosis. A 500-nucleated cell count 
revealed the following differential: neutrophils and 
precursors 18.0%, erythroid precursors 58.6%, 
lymphocytes 7.6%, monocyte 0.4%, eosinophils 
1.0%, plasma cells 1.4%, and blasts 13.0%. Dysplastic 
features were noted in a few erythroid precursors and 
some megakaryocytes (Figures 2 and 3).
Rare dysplastic neutrophils morphologically similar 
to those seen in the peripheral blood smear were also 
found. The Prussian blue stain performed on the bone 
marrow aspirate smear showed adequate stainable iron 
stores (Figure 4A) with many ring sideroblasts (53%, 
100-cell count; Figure 4B).
A flow cytometric study performed on the 
bone marrow aspirate showed the blasts expressed 
CD34, CD38, CD45 (weak), and CD117, and were 
negative for T-cell markers, B-cell markers, CD14 or 
CD64. The bone marrow biopsy sections revealed 
a markedly hypercellular bone marrow (90%) with 
marked erythroid proliferation (Figure 5), and increased 
immature cells, most of which stained positive for 
CD34 (Figure 6A). CD34-positive blasts represented 
approximately 13% of all bone marrow nucleated cells.
In addition, there are many megakaryocytes of 
various sizes, highlighted by CD61 stain (Figure 6B), 
including several micromegakaryocytes. The reticulin 
stain performed on the bone marrow biopsy showed 
mild to moderate myelofibrosis (MF 1-2/3, WHO 2017 
semiquantitative grading of bone marrow fibrosis) 
(Figure 6C).
A diagnosis of myelodysplastic syndrome with 
excess blasts 2 (MDS-EB-2) was made. The bone 
marrow aspirate was sent to Quest Diagnostics Nichols 
Institute (San Juan Capistrano, CA) for cytogenetic 
and molecular tests. Chromosomal analysis revealed 
an abnormal clone with an isochromosome 14 
resulting in trisomy 14 in 20/20 metaphase cells 
analyzed {46,XY,i(14)(q10)[20]}. LeukoVantage®, 
Figure 1. Photomicrograph of the peripheral blood smears showing occasional dysplastic neutrophils. A – The 
neutrophil in the left is dysplastic, with a bilobed nucleus (pseudo-Pelger-Huët anomaly). The neutrophil in the 
right is a normal-appearing band. A few teardrop cells are seen; B – A dysplastic neutrophil with a non-segmented 
nucleus; C – A dysplastic neutrophil with a bilobed nucleus; D – A dysplastic neutrophil with moderately hypogranular 
cytoplasm. [Wright-Giemsa stain, original magnification, × 1000 (A), × 1000 (B-D].
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Myelodysplastic Syndrome (MDS) Panel using next 
generation sequencing demonstrated SF3B1 K700E 
mutation at 38.6% mutation frequency, ZRSR2 H191L 
variant at 49.2% variant frequency, and GATA2 G81R 
variant at 48.0% variant frequency, without alterations 
of ASXL1, ATM, BCOR, CBL, CEBPA, CSF3R, CUX1, 
DNMT3A, ETNK1, ETV6, EZH2, FLT3, IDH1, IDH2, IKZF1, 
JAK2, KRAS, NF1, NPM1, NRAS, PHF6, PTEN, PTPN11, 
RUNX1, SETBP1, SRSF2, STAG2, STAT3, STK11, TET2, 
TP53, U2AF1, and WT1 genes. The patient was 
determined to have high risk disease according to 
the revised International Prognostic Scoring System 
(IPSS-R) and was referred for bone marrow transplant 
evaluation. While waiting for transplant evaluation, he 
was started on azacytidine therapy.
DISCUSSION
These are the three “pillars” that support 
a diagnosis of MDS: 1. persistent and clinically 
unexplained cytopenia in at least one hematopoietic 
l ineage (required); 2. significant morphologic 
dysplasia in one or more hematopoietic lineages 
Table 1. Blood test results at presentation to Harbor-UCLA Medical Center
Test Result Normal Range Test Result Normal Range
Sodium 136 136-144 mmol/L Haptoglobin 27 36-195 mg/dL
Potassium 4.1 3.6-5.1 mmol/L Iron 150 95-182 mcg/dL
Chloride 102 101-111 mmol/L Ferritin 565.3 23.9-336.2 ng/mL
CO2 27 22-32 mmol/L TIBC 363 261-478 mcg/dL
BUN 13 8-20 mg/dL Iron saturation 41 15-50%
Creatinine 0.91 0.64-1.27 mg/dL Folate 9.9 ≥ 5.9 ng/mL
Calcium 9.3 8.9-10.3 mg/dL Vitamin B12 422 180-914 pg/mL
Total protein 7.0 6.4-8.3 g/dL MMA 103 87-318 nmol/L
Albumin 4.5 3.5-4.8 g/dL LDH 209 98-192 U/L
AP 60 38-126 U/L Copper level 91 70-175 mcg/dL
AST 35 15-41 U/L Triglyceride 101 ≤ 149 mg/dL
ALT 69 10-40 U/L Interleukin 2R 2067 532-1891 pg/mL
Total bilirubin 1.7 0.3-1.2 mg/dL TSH 2.449 0.350-4.940 µIU/mL
ALT= Alanine transaminase; AP= Alkaline phosphatase; AST= Aspartate transaminase; BUN= Blood urea nitrogen; LDH= 
Lactate dehydrogenase; MMA= Methylmalonic Acid; TIBC= Total iron binding capacity; TSH= Thyroid-stimulating hormone
Figure 2. Photomicrographs of the bone marrow aspirate smears. A – Erythroid hyperplasia and some erythroblasts 
in apoptosis are evident. A dysplastic megakaryocyte is noted, with two separated round nuclei (arrow); B – Blasts 
(black arrows) are mildly increased. A binucleated erythroid precursor (block arrow) is seen. [Wright-Giemsa stain, 
original magnification, × 400 (A), × 1000 (B)].
Qing X, Cai J, Rock A
5-9Autops Case Rep (São Paulo). 2021;11:e2021274
(with the exception of cases bearing certain qualifying 
cytogenetic aberrations); and 3. cytogenetic and/or 
molecular genetic evidence of clonal hematopoiesis 
(not required, but helpful).4 A diagnosis of MDS can 
be challenging as the morphologic dysplasia and 
cytopenia may be related to factors other than a 
clonal hematologic disorder. Cytopenia can be seen 
in many non-MDS neoplasms in addition to reactive 
Figure 3. Photomicrograph of the bone marrow aspirate smears show mild dyserythropoiesis and some dysplastic 
megakaryocytes. There are a few erythroid precursor cells showing dysplastic features including abnormal nuclear 
budding (A and B), megaloblasts with “nuclei in salami-slice” (B), and binucleation (C). Micromegakaryocytes (D) 
and megakaryocytes with small non-lobated nuclei (E) are present. F. The megakaryocyte shows asynchronous 
nuclear-cytoplasmic maturation, with well granulated cytoplasm and a non-lobated immature nucleus. A dysplastic 
erythroid precursor is also seen. (Block arrows: dysplastic erythroid precursors; black arrow: dysplastic megakaryocytes; 
Wright-Giemsa stain, original magnification, × 1000).
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conditions such as infections, inflammations, metabolic 
deficiencies, the effects of drugs and alcohol intake, 
hemolysis, and autoimmune diseases. Dysplasia itself, 
even if prominent, is not definitive evidence of a clonal 
process because it is frequently seen in patients with 
reactive secondary cytopenia.5-8 Several nutritional 
(such as folic acid, vitamin B12 and copper deficiency), 
toxic (such as heavy metals particularly arsenic, lead 
Figure 4. Photomicrograph of the iron stain of bone marrow aspirate showing adequate iron stores (A) with 
numerous ring sideroblasts (arrows, B). [Iron stain, original magnification, × 100 (A), × 1000 (B)]
Figure 5. Photomicrograph of the bone marrow biopsy shows a hypercellular bone marrow (A) with trilineage 
hematopoiesis and erythroid proliferation (B). [H&E, original magnification, × 40 (A), × 400 (B)].
Figure 6. Photomicrograph of the bone marrow biopsy showing increased immature cells, most of which stain 
positive for CD34 (A). There are many megakaryocytes with various sizes, highlighted by CD61 stain, including 
several micromegakaryocytes (B). Reticulin stain of the marrow biopsy reveals a mild to moderate increase in reticulin 
fibers (C). (A-B, immunocytochemical stain, original magnification, × 200; C, reticulin stain, original magnification, 
× 200).
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and zinc, drugs) and other factors (such as congenital 
disorders, infections, and autoimmune disorders) can 
cause myelodysplastic changes but not atypia.
After emerging in December 2019 in Wuhan, 
China, the coronavirus disease 2019 (COVID-19) has 
rapidly spread and evolved into a global pandemic. 
The disease is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), but the 
pathophysiology of this infection is not completely 
understood. The disease affects multiple organs 
including hematopoietic system. In the peripheral 
blood, both quantitative and qualitative abnormalities 
have been reported. CBC and peripheral blood 
smear findings commonly reported in COVID-19 
patients include anemia, leukopenia, leukocytosis, 
neutropenia, neutrophilia, lymphopenia, monocytosis, 
monocytopenia, eosinopenia, thrombocytopenia, 
thrombocytosis, and leukoerythroblastic picture.9-13 
Morphologic aberrations were reported mainly in 
leukocytes and platelets, including changes usually 
found in MDS such as dysplastic neutrophils with 
hypogranular cytoplasm and/or hyposegmented 
nucleus (acquired Pelger-Huët anomaly) as well as 
giant platelets.12-15 Taken together, COVID-19 and MDS 
may present with similar peripheral blood findings. 
Further studies are needed to understand if and how 
hematopoiesis is involved in COVID-19 pathogenesis, 
and if COVID-19 patients have a higher susceptibility 
for secondary hematologic diseases.
Prieto-Pérez et al.16 studied post-mortem 
bone marrow samples from 17 patients who died 
with a diagnosis of COVID-19, and in most cases 
found increased bone marrow cellularity, scattered 
macrophages with engulfed erythrocytes and 
erythroblasts resembling the changes observed in 
HLH, left-shifted myeloid hyperplasia, clusters of 
megakaryocytes, and interstitial aggregates of CD8 
positive lymphocytes. Our patient might have had 
HLH when he was diagnosed with COVID-19 at the 
outside hospital, given the very high serum ferritin 
level and the hemophagocytosis in his bone marrow. 
However, at Harbor-UCLA Medical Center, he had 
only mild hyperferritinemia, without fulfilling other 
diagnostic criteria for HLH. It is likely that his HLH had 
been largely resolved, although the only treatments 
he received were acetaminophen and ibuprofen. In 
the study conducted by Prieto-Pérez et al.16, it was 
not mentioned if COVID-19 patients’ bone marrow 
can show myelodysplastic features, possibly because 
myelodysplasia is best evaluated on bone marrow 
aspirate smears which is unobtainable post-mortem.
The diagnosis of MDS may be particularly 
challenging in patients with COVID-19 in whom it is 
hard to determine whether the peripheral blood and 
bone marrow abnormalities are caused by COVID-19 
or MDS. In difficult cases, clinical follow-up may be 
required for the differentiation. Due to the diagnostic 
uncertainty, the patient was referred to our hospital 
for further diagnosis and management.
At our hospital, the diagnosis of MDS was made 
based on the presence of persistent pancytopenia 
including macrocytic anemia (folate and vitamin B12 
deficiency had been excluded), marked bone marrow 
hypercellularity, trilineage myelodysplasia, numerous 
ring sideroblasts, and 13% myeloblasts. The diagnosis 
was further supported by abnormal cytogenetic and 
molecular results.
Blasts are normally 1% to 5% of bone marrow 
cells and are usually not seen in peripheral blood. 
Although up to 2% blasts have been reported in the 
peripheral blood of COVID-19 patients,13 an increase 
in blasts in bone marrow in the context of morphologic 
dysplasia and prolonged cytopenia in the absence of 
growth factor therapy, as seen in the present case, 
is a very strong indicator of MDS. To the authors’ 
knowledge, increase in bone marrow blasts (≥5%) has 
not been reported in reactive conditions such as acute 
viral infection in the literature.
A cytogenetic abnormality characteristic of 
MDS confirms the diagnosis, but cytogenetic 
abnormalities are only seen in about 50% of MDS 
cases. According to the 2017 WHO classification, 
MDS-associated cytogenetic abnormalities that 
are sufficient to confirm a diagnosis of MDS in a 
cytopenic patient include loss of chromosome 7 or 
del(7q), del(5q), isochromosome 17q or t(17p), loss 
of chromosome 13 or del(13q), del(11q), del(12p) or 
t(12p), del(9q), idic(X)(q13), t(11;16)(q23.3;p13.3), 
t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21.2), t(2;11)
(p21;q23.3), inv(3)(q21.3;q26.2)/t(3;3)(q21.3;q26.2), 
and t(6;9)(p23;q34.1).3 On the other hand, some 
common cytogenetic abnormalities seen in MDS, 
i.e., gain of chromosome 8, del(20q), and loss of Y 
chromosome, can be seen in normal aged persons 
or in individuals with non-MDS caused cytopenia,17-19 
and are not considered definitive evidence of MDS. 
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In our patient, chromosomal analysis revealed an 
abnormal clone with an isochromosome 14 resulting 
in trisomy 14 in 20/20 metaphase cells analyzed 
{46,XY,i(14)(q10)[20]}. Trisomy 14/14q is extremely 
rare in myeloid neoplasms, mainly seen in MDS and 
chronic myelomonocytic leukemia (CMML), and less 
frequently observed in AML or other myelodysplastic/
myeloproliferative neoplasms (MDS/MPN).20 Associated 
with intermediate to good prognosis, this abnormality 
occurs as an isolated change in less than 0.5% of 
patients with MDS and is typically found in older, male 
patients with and without excess blasts.20 In the largest 
series of myeloid neoplasms with isolated trisomy 14 
(n=16) published so far, 5/16 patients showed an 
isolated isochromosome 14q [i.e., i(14)(q10)] resulting 
in trisomy 14q.21 We report, for the first time, this 
cytogenetic aberrancy as isolated change in a young 
MDS patient.
Acquired somatic gene mutations are seen in 
the vast majority of MDS patients at diagnosis, with 
several commonly recurring mutations such as SF3B1, 
TET2, ASXL1, SRSF2, DNMT3A, RUNX1, U2AF1, TP53, 
EZH2, STAG2, IDH1/IDH2, CBL, NRAS, and BCOR. 
Many myeloid-associated somatic mutations have been 
identified in healthy older individuals without MDS,22-
23 known as “clonal hematopoiesis of indeterminate 
potential” (CHIP). For these reasons, genetic mutations 
alone cannot be used to support clonality or make 
a diagnosis of MDS, even with cytopenia, in the 
2017 WHO classification.3 Mutation of SF3B1 was 
detected in our patient, which is closely associated 
with MDS with ring sideroblasts and MDS/MPN with 
ring sideroblasts and thrombocytosis. Given the young 
age of our patient, the detected SF3B1 mutation is 
very likely disease-related rather than CHIP-associated. 
Therefore, in our case, the presence of numerous ring 
sideroblasts and the detection of SF3B1 mutation 
further support the diagnosis of MDS.
CONCLUSION
Peripheral blood of COVID-19 patients may show 
cytopenia and dysplastic neutrophils, which are features 
commonly seen in patients with MDS, making accurate 
diagnosis of MDS more challenging during the COVID-
19 pandemic. Clinicians should be aware that although 
commonly seen in elderly patients, MDS can occur in 
young individuals. Besides cytopenia and myelodysplasia, 
macrocytic anemia (without vitamine B12 or folate 
deficiency) and ring sideroblasts increase the suspicion 
of MDS. If present, excess blasts (≥5%) and/or MDS-
qualifying cytogenetic abnormalities support a diagnosis of 
MDS. Genetic mutations alone cannot be used to support 
clonality or make a diagnosis of MDS, but could be helpful 
in some situations. In difficult cases, a close follow-up of the 
patient may be required for further diagnostic clarification.
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